Glucophage Trio
Glimepiride · Metformin · Voglibose
Utilised to manage complex glycaemic fluctuations to alleviate chronic hyperglycaemia and support tissue insulin sensitivity.
- Category
- Diabetes Management
- Active ingredients
- Glimepiride · Metformin · Voglibose
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1mg + 0.2mg + 500mg
Prescription and consultation requirements for Glucophage Trio vary by destination and are determined by the fulfilment partner.
Glucophage Trio details
- Condition
- Type 2 Diabetes Mellitus
- Alternative names
- glimepiride, metformin, voglibose
- Therapeutic class
- Antidiabetic Combination
- Pharmacological class
- Sulfonylurea, Biguanide, Alpha-Glucosidase Inhibitor Combination
- Contraindications
- severe renal impairment; diabetic ketoacidosis; congestive heart failure
- Minor side effects
- diarrhoea; nausea; flatulence
- Moderate side effects
- hypoglycaemia; weight gain; metallic taste
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Merck
- Onset Time
- 1–2 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Alcohol; Contrast Media; NSAIDs
- Age restrictions
- Approved for adults.
Serious side effects
lactic acidosis, requires immediate medical attention; severe hypoglycaemia, requires immediate medical attention
Patient summary
utilised to manage complex glycaemic fluctuations to alleviate chronic hyperglycaemia and support tissue insulin sensitivity.
Mechanism of action
Stimulates pancreatic insulin, lowers liver glucose production, and slows intestinal carbohydrate breakdown concurrently.
Pregnancy and breastfeeding
TGA Category C: Avoid during pregnancy due to developmental risks. Breastfeeding: Not recommended.